NeuroOne Medical Technologies Corp (NMTC)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$0.92-6.19%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge NeuroOne Medical Technologies Corp’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	About $3.8M	—
FY 2027 · Q1
Revenue	—	3.36M
EPS	—	-0.17
FY 2026 · Annual
Revenue	About $10.5M	—
FY 2027 · Annual
Revenue	—	13.33M
EPS	—	-0.633
FY 2028 · Annual
Revenue	—	18.19M
EPS	—	-0.34

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
No new material legal or audit issues arise	A supporting condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is No new negative legal or audit events.	Under Pressure	New material legal or audit issues reported	Audit issue reported vs no new issues Item 4.02 filing reports Audit Committee determined non-reliance on Q1 2026 interim financial statements. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve earnings per share	A primary condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is EPS loss narrows toward -$0.51 next fiscal year.	Improving	EPS loss worsens beyond -$0.51 in FY27	Diluted EPS: $-0.28 per share FY2026-Q3; GAAP. Published target: EPS loss narrows toward -$0.51 next fiscal year. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-0.28 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3a2c011e-16d9-40ac-92c9-340e73444034. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reach $2.4M product revenue in Q2 2026	A supporting condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is >=2.4 USD_MILLIONS.	Broken	Q2 revenue falls below $2.4M	Product revenue: $33,748 FY2022-Q1; reported segment. Published target: >=2.4 USD_MILLIONS. The stored target says 2026-Q2; this source reports FY2022-Q1. Fiscal/calendar alignment needs review. Source published Feb 14, 202233,748 USD · source valueLast status assessment Oct 24, 2026 Measurement source Product · reported segment FY2022-Q1 · Period ending Dec 31, 2021 Source: stock_segment_revenue. Reference: 2022-Q1. Source status: vendor observation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve at least $10.5M revenue in fiscal 2026	A primary condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is >=10.5 USD_MILLIONS.	Broken	Revenue falls below $10.5M in fiscal 2026	Revenue: $1.973M FY2026-Q3; GAAP. Published target: >=10.5 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 13, 20261,973,105 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3a2c011e-16d9-40ac-92c9-340e73444034. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

No new material legal or audit issues arisePublished status: Under Pressure
Reduce losses and improve earnings per shareDiluted EPS: $-0.28 per share
Reach $2.4M product revenue in Q2 2026Published status: Broken
Achieve at least $10.5M revenue in fiscal 2026Published status: Broken

Next proof point

Dec 15, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.6%Typical daily move · historical

Downside history

-84.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NeuroOne Medical Technologies Corp outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk medical-device growth story, not yet a proven compounder, because it remains loss-making. The multi-year view is supported by progress in product revenue and international readiness, while recent results leave the thesis in a watch state.

What's priced into NeuroOne Medical Technologies Corp

The valuation model describes NMTC as cheap versus peers, with a negative expectations gap, though model confidence is low. The priced-in assessment is tagged justified, and no fragility gates fired, so the evidence does not point to unusually fragile expectations.

What the fundamentals likely do

Near term, earnings risk is elevated after two recent misses and a reported risk of another miss; financial performance remains weak. On the multi-year view, management is on track with its fiscal 2026 product-revenue goal, OneRF commercialization, and ISO certification, while the broader healthcare backdrop has improved.

What NeuroOne Medical Technologies Corp hinges on

The next call matters: a guidance cut would add to the recent execution concerns. The thesis also depends on OneRF adoption and international expansion translating into sustained growth, while weaker job growth could pressure cyclical healthcare names; continued strength from sector bellwethers would support the backdrop.

Bottom line

Over the next 1 to 3 years, NMTC has credible commercialization milestones but remains a loss-making, high-risk business with weak recent performance and a meaningful near-term earnings concern. The long-term thesis hinges on turning product growth and regulatory progress into more reliable financial execution. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.